<DOC>
	<DOCNO>NCT01652898</DOCNO>
	<brief_summary>The study consist Pilot Phase ( assess safety local tolerability high AOP LDLA202 dose versus placebo ) Main Treatment Phase ( compare PK , PD safety tolerability AOP LDLA202 , ONO LDL50 esmolol bolus administration measurement blood concentration landiolol , esmolol metabolite , monitor ECG , blood pressure adverse event ) .</brief_summary>
	<brief_title>A Pharmacokinetic , Pharmacodynamic , Safety Study With AOP LDLA202 , ONO LDL50 Esmolol Healthy Volunteers</brief_title>
	<detailed_description>A single centre prospective , randomize , double blind study consist local safety Pilot Phase triple-cross-over Main Study Phase . In pilot phase , 3 subject administer bolus AOP LDLA202 vs. placebo ( 0.9 % saline ) simultaneously ( vein body side ) . Following treatment first subject per cohort assume safety concern arise , second third subject treat safety interval least 3 hour dose individual subject . On Day 3 dose safety follow-up assessment do adverse event report sponsor 's medical monitor . Assuming safety concern arise , sponsor 's medical monitor give green light conduct Main Treatment Phase write . In main phase , 12 subject treat AOP LDLA202 , ONO LDL50 esmolol . Three dos per subject day ( =treatment period ) , administer via big superficial vein , plan least 1 hour observation period bolus injection . Each subject , confirm eligible , complete three treatment period total main phase study . ECG , blood pressure , local tolerability adverse event monitor .</detailed_description>
	<mesh_term>Esmolol</mesh_term>
	<criteria>Male female human subject , age 1845 year , Caucasians Body weight least 50 kg , maximum 90 kg . Bodymass index 18.5 30.0 kg/m2 . Subjects without clinically relevant abnormality determine baseline medical history , physical examination , blood pressure , heart rate ear temperature screen . Subjects without clinically relevant abnormality determine blood count , coagulation test , biochemistry , infectious disease screening , urinalysis , ECG , 2D Echo screening . Subject willing able undergo procedure require protocol give write informed consent . Agreeing use prescription counter medication No history presence alcoholism drug abuse Subjects history presence clinically relevant cardiovascular , renal , hepatic , ophthalmic , pulmonary , neurological , metabolic , hematological , gastrointestinal , endocrine , immunological , psychiatric skin disease . Subjects bradycardia ( heart rate 50 bpm ) , tachycardia ( heart rate 100 bpm ) , hypotension ( systolic blood pressure 100 mmHg , and/or diastolic blood pressure 70 mm Hg ) screening , history clinically relevant arrhythmia . Subjects clinically relevant cardiac supraventricular ventricular arrhythmia . Subjects atrioventricular block grade II III , sick sinus syndrome , sinoatrial block congestive heart failure . Participation clinical drug study bioequivalence study 60 day prior present study . History malignancy serious disease . Any contraindication blood sample . History i.v . drug abuse . Subjects positive HIV test , HBsAg Hepatitis C test acute , subacute chronic infectious disease . Known history hypersensitivity IMP . Refusal abstain smoke consumption tobacco product 48 hour drug administration study period . Refusal abstain alcohol , caffeine , xanthine , grapefruit contain food drink 72 hour drug administration study period . Refusal abstain strenuous activity 7 day screen endofstudy examination , study period . Subjects anomaly venous arterial vessel forearm systemic vascular disease . Pregnancy and/or breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>PK</keyword>
</DOC>